Dr David Tan is a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore.  His primary clinical and research interests are in gynaecological cancers and the development of novel anti-cancer therapeutic agents. 

Dr Tan graduated with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London, and obtained his MRCP(UK) in 2005. In that same year, he was awarded a Cancer Research UK (CRUK) Clinical Research Fellowship at The Institute of Cancer Research (the academic partner institution of The Royal Marsden Hospital), London, where he did research in ovarian and breast cancers and obtained his PhD in Oncology. He subsequently completed his specialist training in Medical Oncology at The Royal Marsden Hospital, London.  After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he went on to complete another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore. 

In addition to his clinical and academic duties, he is currently also the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS).  He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Therapeutics Centre in A*STAR Singapore.  He has authored over 50 peer-reviewed scientific papers and abstracts and received several awards for his research as well.

Sponsored by: 

Remi Nout was board certified as Radiation Oncologist in the Netherlands in 2008. During his residency he was involved in the PORTEC (Post Operative Radiation Therapy for Endometrial Cancer) trials. With the thesis titled ‘PORTEC- Reducing Overtreatment and Improving Quality of Life’ he obtained a PhD degree in 2013.The outcomes of the PORTEC-2 trial and long-term quality of life among PORTEC-1 survivors formed the basis of this thesis. He combines clinical work at the Leiden University Medical Center in the Netherlands with research activities and involvement in the PORTEC trials and is co-principal investigator in PORTEC-4. Main research areas include health related quality of life (endometrial cancer, cervical cancer collaborating in the EMBRACE study, rectal cancer), translational research prognostic and predictive markers in endometrial cancer, and brachytherapy. He is active in the GEC-ESTRO GYN group, currently involved a task group for the target concept in endometrial cancer, vaginal recurrences and primary vaginal cancer. He is board member of the Dutch Platform for Radiotherapy of Gynaecological Malignancies and representative in the Dutch Gynecologic Oncology Group. Since March 2014 he was awarded a two-year Clinical Fellowship from the Dutch Cancer Society titled ‘Image Guided Brachytherapy’ with a focus on rectal and gynaecological cancers. During this fellowship he will work in the radiotherapy departments of the Jewish General Hospital in Montreal, Canada; Aarhus University Hospital, Denmark; University Medical Center Utrecht, Erasmus Medical Center Rotterdam and the Leiden University Medical Center in the Netherlands.

Sponsored by: 

Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Women’s Cancer Moonshot Program (focused on ovarian and breast cancers).

Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina. His research is focused in three main areas: 1) mechanisms of angiogenesis and metastasis in ovarian cancer; 2) effects of neuroendocrine stress hormones on ovarian cancer growth and progression, 3) development of new strategies for systemic in vivo siRNA delivery. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. Dr. Sood has published over 460 peer-reviewed articles and holds 15 patents related to novel drugs and technologies. He is an elected member of the American Society for Clinical Investigation (ASCI) and an elected fellow of the American Association for the Advancement of Science (AAAS).

Sponsored by: